Adult Stem Cells
Adult Stem Cells
Adult Stem Cell Research Network
Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair PDF Print E-mail
SAN DIEGO, Jul 27, 2010 (BUSINESS WIRE) -- Cytori Therapeutics received expanded European approval (CE Mark) for its Celution(R) System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. The new indications include key medical applications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds, such as those resulting from Crohn's disease. This broadens Cytori's ability to offer the Celution(R) System to patients and hospitals and further supports the company's efforts to gain treatment reimbursement.
Read more...
 
Nanotechnology and stem cells rejuvenate arteries PDF Print E-mail

July 26, 2010

A combination of nanotechnology and adult stem cells has been shown to destroy arterial plaque atherosclerosis in the hearts of pigs. Animals that received stem cells also showed signs of new blood vessel growth and restoration of artery function, according to the study reported at the American Heart Association's Basic Cardiovascular Sciences 2010 Scientific Sessions.

The study was conducted at the Department of Internal Medicine and Research Center of Regenerative Medicine, Ural State Medical Academy in Yekaterinburg, Russia. Nanoparticles were infused into the heart of pigs, along with adult stem cells, then heated by laser light until they burned away arterial plaque. The volume of plaque shrunk an average of 28.9 percent immediately after treatment across the three treatment groups, and six months later it had declined 56.8 percent on average. In the control group, plaque volume increased an average of 4.3 percent.

Read more...
 
Tests begin on stem cell cure for rare heart disease PDF Print E-mail
Cardiologists hope new treatment can prolong the lives of patients with dilated cardiomyopathy

July 25, 2010

Doctors are investigating whether patients with an irreversible heart condition can prolong their lives by having stem cells taken from their hip and injected into the damaged organ.

Experts at the Barts and the London Heart Attack Centre hope their work will lead to a major breakthrough for the UK's estimated 30,000 sufferers with dilated cardiomyopathy (DCM). The rare condition causes the heart muscle wall to become thin and floppy, making the heart progressively less able to pump blood around the body. Drug treatment can be of limited benefit, and ultimately patients deteriorate to the extent that they will die unless they receive a new heart.

Read more...
 
Scientists 'reprogram' mouse fat cells into clinically useful stem cells PDF Print E-mail
Tampa, Fla. (July 26, 2010) - Australian scientists from the Monash Institute of Medical Research have "reprogrammed" adult mouse fat cells and neural cells to become stem cells that can differentiate into a variety of different cells (pluripotency). The cells, called "induced pluripotent stem cells" (iPS), are nearly identical to the naturally occurring pluripotent stems cells, such as embryonic stem cells, which are highly pluripotent, in short supply and their access restricted in the U.S.

The study is published in issue 19(5) of Cell Transplantation and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ .

"Induced pluripotent stem cells have revolutionized cell reprogramming," said the study's lead author, Dr. Paul J. Verma. "One challenge is to find the most appropriate cell for reprogramming. Our study demonstrated that both neural stem cells (NSCs) and adipose tissue-derived cells (ADCs) from adult mice expressed genetic pluripotency and could differentiate into the three germ layers, endoderm, mesoderm and ectoderm. The ADCs were the most amenable to reprogramming."

Read more...
 
MESOBLAST RECEIVES TGA REGULATORY APPROVAL TO COMMERCIALLY MANUFACTURE ADULT STEM CELL PRODUCTS PDF Print E-mail
Melbourne, Australia; 21 July 2010: Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; ADR:MBLTY), today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cell (MPC) products.

Under this licence, Mesoblast will now make commercially available to doctors and hospitals across Australia manufactured MPC products for a patient's own, or autologous, use in the repair and regeneration of their damaged tissues. The cells will be manufactured under an agreement between Mesoblast and the TGAlicensed contractor Cell Therapies Pty Ltd.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 Next > End >>

Page 1 of 7
All information is © 2010 by the Cell Therapy Foundation
Adult Stem Cells
Adult Stem Cells

*Designates sites with available clinical trials.

Click Here to Update your Lab

ASCR Network RSS

ASCR Latest
adult stem cells